Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
28 hedge funds and large institutions have $6.25M invested in Viracta Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 17 closing their positions.
693% more call options, than puts
Call options by funds: $325K | Put options by funds: $41K
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
32% less funds holding
Funds holding: 41 → 28 (-13)
37% less capital invested
Capital invested by funds: $9.95M → $6.25M (-$3.7M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
76% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$3.66M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$376K |
| 3 |
RM
RP Management
New York
|
+$291K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$81.8K |
| 5 |
Millennium Management
New York
|
+$51.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$662K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$289K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$38K |
| 4 |
Jane Street
New York
|
-$36K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$29K |
VIRX Hedge Fund Activity: Q3 2020 in Review
28 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2020, worth a combined $6.25M — down 37% from $9.95M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of VIRX and 4 opened new positions — a net loss of 13 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was BVF Inc, adding an estimated $3.66M. The largest seller was Nantahala Capital Management, cutting an estimated $662K.
- 28 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2020, down from 41 in Q2 2020.
- Funds reported $6.25M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2020, down 37% quarter-over-quarter.
- 4 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2020 and 17 closed out, a net change of -13 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2020 was BVF Inc, an estimated $3.66M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2020 was Nantahala Capital Management, an estimated $662K sold.
Based on aggregated 13F filings for Q3 2020.